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Abstract
Aim: Stimulation of the nitric oxide (NO) – soluble guanylate (sGC) - protein kinase G (PKG) pathway confers protection
against acute ischaemia/reperfusion injury, but more chronic effects in reducing post-myocardial infarction (MI) heart failure
are less defined. The aim of this study was to not only determine whether the sGC stimulator riociguat reduces infarct size
but also whether it protects against the development of post-MI heart failure.
Methods and Results: Mice were subjected to 30 min ischaemia via ligation of the left main coronary artery to induce MI
and either placebo or riociguat (1.2 mmol/l) were given as a bolus 5 min before and 5 min after onset of reperfusion. After
24 hours, both, late gadolinium-enhanced magnetic resonance imaging (LGE-MRI) and 18F-FDG-positron emission
tomography (PET) were performed to determine infarct size. In the riociguat-treated mice, the resulting infarct size was
smaller (8.562.5% of total LV mass vs. 21.8%61.7%. in controls, p = 0.005) and LV systolic function analysed by MRI was
better preserved (60.1%63.4% of preischaemic vs. 44.2%63.1% in controls, p = 0.005). After 28 days, LV systolic function by
echocardiography treated group was still better preserved (63.5%63.2% vs. 48.2%62.2% in control, p = 0.004).
Conclusion: Taken together, mice treated acutely at the onset of reperfusion with the sGC stimulator riociguat have smaller
infarct size and better long-term preservation of LV systolic function. These findings suggest that sGC stimulation during
reperfusion therapy may be a powerful therapeutic treatment strategy for preventing post-MI heart failure.
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Introduction
Chronic heart failure (CHF) is a serious consequence of
myocardial infarction (MI) and is associated with high mortality
and morbidity. Reducing infarct size acutely after an ischemic
event is assumed to reduce the risk of detrimental post-MI
remodelling [1] and ensuing CHF. While much effort has gone
into the identification of acutely protective strategies to reduce
infarct size, relatively little has been directed to actually
documenting their long-term post-MI effects.
The NO – sGC - PKG pathway is known to play an important
role in the acute protection against cardiac reperfusion injury. We,
and others, could show that an increase of cyclic GMP via
phosphodiesterase 5 inhibition can afford powerful cardioprotec-
tion when applied at the onset of reperfusion. [2,3] The same is
seen with the stimulation of soluble or particular guanylate cyclase.
[4,5] All these interventions seem to require PKG as their
downstream target. [6,7] NO not only can have a trigger role in
this pathway at the level of sGC but also appears to be a
downstream effecter by directly S-nitrosylating protective proteins.
[8,9].
Recently, a new class of drugs, the so-called sGC stimulators,
entered the clinical development for the treatment of pulmonary
hypertension. Stimulators of sGC have a dual mode of action: they
both sensitise sGC to endogenous NO by stabilizing the NO-sGC
binding and also directly stimulate sGC independently of NO via a
second binding site. The sGC stimulator riociguat, has recently
undergone Phase III clinical trials in patients with several subforms
of pulmonary arterial hypertension (PAH) and with chronic
thromboembolic pulmonary hypertension (CTEPH). Exercise
capacity was the primary endpoint for these studies and in all
cases riociguat increased the patients’ 6-minute-walking-distance.
[10–12] Additionally, improvements were observed across sec-
ondary endpoints, including pulmonary hemodynamics, functional
class and time to clinical worsening. Remarkably, riociguat is the
first drug that has consistently demonstrated efficacy in both
CTEPH and PAH.
Riociguat also produced positive clinical effects in smaller proof-
of-concept studies in patients with pulmonary hypertension
secondary to left heart failure, interstitial lung disease and chronic
obstructive pulmonary disease. [13] In animal models riociguat
has been shown to be organ protective against cardiac and renal
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damage from hypertension and chronic renal failure and volume
overload. [13–15].
In this study we tested the effects of riociguat on MI size and
post-MI CHF development in a mouse model of ischaemia/
reperfusion. Gadolinium-enhanced magnetic resonance imaging
(MRI) as well as FDG-PET was used to determine the resulting
infarct size post-MI, while echocardiogram was used to measure
LV function over a 28 day recovery period.
Methods
All procedures were conducted in accordance with the Animals
(Scientific Procedures) Act 1986 (PPL 80/2393) and the University
of Cambridge Policy on the Use of Animals in Scientific Research
and approved by the Home Office (UK) Animals Scientific
Procedures Department (ASPD).
In vivo mouse model of myocardial infarction
Infarct size following ischaemia/reperfusion an in situ open
chest mouse model was measured as previously described. [16]
Briefly, male C57/BL6 mice were anaesthetised with either
pentobarbital (2 h reperfusion model) or gaseous isoflurane (24 h
reperfusion model) and subjected to 30 min occlusion via a snare
around the left anterior descending branch of the left coronary
artery followed by either 2 h or 24 h reperfusion. Mice received
either intravenous saline or 1.2 mmol/l riociguat 5 min before the
onset of reperfusion via tail vein injection. L-NAME or KT5823
was given 10 min prior to the riociguat treatment. Cardiac
Troponin I was measured in blood serum taken prior to heart
removal at the end of each experiment. More details are described
in the online supplement.
Blood pressure measurement
Blood pressure was either measured non-invasively using a tail
cuff apparatus or through left ventricular catheterization via the
right carotid artery using a 1.2 F pressure-catheter (Scisense Inc.,
London, Canada).
Echocardiography assessment of cardiac function
Transthoracic echocardiography was performed on mice
anesthetized with 2% isoflurane, using a Vevo 770 ultrasound
system (Visual Sonics, Toronto, Canada). Hearts were visualised in
the two dimensional short-axis plane and analysis performed in M-
mode in the consistent plane of the papillary muscles. Ejection
fraction (EF) was calculated from end-systole and end-diastole
measurements in at least three repeated cardiac cycles. Fractional
shortening was calculated by the Simpson’s method.
MRI and PET imaging
Animals were anaesthetised with gaseous isoflurane both for
induction (3% in 1 l/min O2) and maintenance (1.5–2% in 1 l/
min O2). A pressure sensor for respiration rate was used to monitor
anaesthesia depth, rate was maintained in the range 30–45 breaths
per minute. Prospective gating of the MRI sequences was achieved
with ECG monitoring. Body temperature was monitored using a
rectal thermometer and a flowing-water heating blanket was used
to maintain animal temperature at 37uC throughout the exper-
iment.
MRI was performed at 4.7 T with a Bruker BioSpec 47/40
system (Bruker Inc., Ettlingen, Germany). A birdcage coil of
12 cm was used for signal excitation and a 2 cm surface coil for
signal reception with the animals positioned prone. After initial
localization images, 4-chamber and 2-chamber views were
acquired (FISP, TR/TE 7 ms/2.4 ms, 13–20 frames, 3.5 cm
FOV, 2566256 matrix, 1 mm slice thickness, bandwidth 64 kHz,
Figure 1. Effects of riociguat on infarct size after acute myocardial infarction. (A) Riociguat reduced infarct size significantly when given
just before the onset of reperfusion after 30 min ischaemia in an acute in vivo mouse model. The protection was unaffected by the NOS inhibitor L-
NAME, but blunted when the PKG inhibitor KT5823 was administered prior to riociguat. Open symbols represent individual experiments and closed
symbols are means 6SEM. (B) Troponin I level in blood serum taken at the end of the 120 min reperfusion further support the results of the
histological measurements. *p,0.001.
doi:10.1371/journal.pone.0083910.g001
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flip angle 20u, NEX2). Using these scans as a reference, short axis
slices were arranged perpendicularly to both the long-axis views to
cover the left ventricle (LV) (FISP, TR/TE 7 ms/2.4 ms, 13–20
frames, 3.5 cm FOV, 2566256 matrix, 1 mm slice thickness,
bandwidth 64 kHz, flip angle 20u, NEX2). Full LV coverage was
achieved with no slice gap with 8–10 slices.
DENSE MRI [17] was acquired (3 short-axis slices encoding
from end diastole to end-systole, 1 mm thick, TR/TE ,200 ms/
9.5 ms, 3.5 cm FOV, 128 matrix, bandwidth 64 kHz, flip angle
90u, 4 NEX with CANSEL. [18].
After the acquisition of the standard cine protocol and DENSE,
late gadolinium enhancement was performed. [19] Contrast agent
was injected in situ (Gadovist, Bayer; 0.3 mmol/kg i.v.). Within the
first 15 min after injection, IR images were acquired (FLASH,
FOV 3.5 cm, 2566256, 0.8 mm slice thickness with 0.2 mm gap
between adjacent slices TE= 2.8 ms, TR=550–750 ms, FLASH
TR 7 ms, bandwidth 64 kHz, flip angle 60u, 1 NEX, 0.8 mm,
0.2 mm gap, selective inversion 0.8 mm thickness with 5 ms sech
shaped pulse).
Animals were transferred on the same bed to the Cambridge
PET-MRI scanner. [20] Injection of 25 MBq 18F-FDG was
performed in situ, and list-mode gated PET acquired continuously
for 45 min.
Image Analysis
Delineation of the LV at each phase of the cardiac cycle
excluded the papillary muscles and trabeculae throughout. The
regions from each slice were combined using Simpson’s rule to
provide LV mass, end diastolic volume (EDV), end systolic volume
(ESV), stroke volume (SV) and ejection fraction (EF) using
Segment v1.9. [21] The infarcted regions were manually
delineated on the IR images. Values are expressed as ratios of
the LV mass as measured from the cine images.
DENSE MRI images were analysed with in-house code using
Matlab: phase images were extracted and unwrapped [22] to
obtain displacement maps. The Green strain tensor (E) was
calculated from the Jacobian matrix (F) by means of E= (F9F-I)/2.
The tensor was then decomposed into radial and circumferential
strain components. Global strains were obtained by integrating
values over the LV.
FDG-PET Images were reconstructed using a 3D filtered
backprojection algorithm in 8 cardiac phases and temporal frames
of 15 min. The cardiac phase correspondent to end-diastole was
selected for each subject. Images from PET and MRI were co-
registered manually with a rigid transformation using SPM-Mouse
bulk registration tool. [23].
Infarct size was assessed in the FDG-PET images by manual
delineation in the final frame. Voxels where intensity was below
50% of the maximum heart uptake were considered non-viable,
following Stegger et al. [24].
Relative mRNA quantification by RT-PCR
Details can be found in the online supplement.
Figure 2. Infarct size assessment with LGE-MRI and effects of riociguat on left ventricular ejection fraction 24 h after myocardial
infarction. (A) Infarct size was determined with LGE-MRI 24 h after the ischemic event showing that acute riociguat treatment markedly reduced
infarct size. *p,0.005. (B) There was a good correlation between infarct size assessment via histological TTC staining (representative images
depictured on the right) and LGE-MRI (left). Epicardial and endocardial borders have been manually added for clarity. (C) Riociguat significantly
increased LV ejection fraction compared to untreated control measured by MRI 24 h after the ischemic event. Open symbols represent individual
experiment and closed symbols are means 6SEM. *p,0.005.
doi:10.1371/journal.pone.0083910.g002
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Data analysis
All data are presented as mean 6 standard error of the mean
(SEM). The infarct size is shown as percentage of area at risk. The
blood pressure values are plotted as percentage of the respective
baselines. Differences among groups were compared by one-way
ANOVA with Turkey’s post hoc test. A value of p,0.05 was
considered significant.
Results
Effects of riociguat on infarct size
Mice treated with riociguat at the onset of reperfusion showed a
marked reduction of infarct size after 30 min LCA occlusion
followed by 2 h reperfusion. The protection was still present when
the NOS inhibitor L-NAME was given prior to the riociguat
treatment, while the PKG blocker KT5823 blocked the riociguat
effect (Fig 1A), suggesting a NO-independent effect through PKG
signalling. Infarct size was determined with tetrazolium staining
(Fig 1A) and blood serum levels of cardiac Troponin I (Fig 1B).
The profound protection affected by riociguat was still present
after 24 h when infarct size was determined by late gadolinium
enhancement LGE-MRI (Fig 2A, supplemental Table 1 in File
S1). Fig 2B shows representative images of LGE-MRI and
standard protocol TTC staining for comparison from the same
heart after 24 h of infarction. Both techniques for assessment of
infarct size show a good correlation in our hands. [19].
Furthermore, FDG-PET was used as an additional technique to
assess functional infarct size data. As shown in Figure 3A, the
direct comparison of infarct size measurements between LGE-
MRI and PET reveal a good correlation between these two
techniques. Fig 3B depicts example images of LGE-MGI and PET
as well as the overlay of both techniques. Representative films of
merged LGE-MRI/PET can be seen for control and riociguat-
treated mice in the online supplement (Videos S1 and S2).
Figure 3. Assessment of infarct size via consecutive LGE-MRI and FDG-PET. (A) There was a good correlation between infarct size measured
with LGE-MRI and FDG-PET. Acute riociguat treatment at reperfusion (blue) resulted in smaller infarcted areas than untreated controls (black). (B)
Representative overlay images of LGE-MRI and FDG-PET of a mouse in the control group. Eepicardial and endocardial borders have been manually
added on the LGE images for clarity. The infarct area, represented by hyperenhancement in the MRI images, matches an area of hypoenhancement
on the PET.
doi:10.1371/journal.pone.0083910.g003
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Figure 4. Improvement of LV ejection fraction following riociguat treatment 28 days post-MI. (A) Early riociguat treatment continued to
result in improved LV ejection fraction, suggesting beneficial effects on post-MI remodelling. *p,0.004. (B) Representative images of M-mode traces
of control (top) and riociguat treated (bottom) mice hearts.
doi:10.1371/journal.pone.0083910.g004
Figure 5. Assessment of cardiac deformation after myocardial infarction. Radial (A) and circumferential (B) strain as representative markers
of heart deformation were obtained 24 h after infarct with LGE-MRI Both parameter show marked improvement in heart function after treatment
with riociguat (blue) compared to untreated control (black). Representative images are also shown for each of the parameters. Endocardial and
epicardial borders have been delineated on the LGE images, hypokinetic areas have been marked in red in the displacement images.
doi:10.1371/journal.pone.0083910.g005
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Effects of riociguat on cardiac function and heart failure
development
Left ventricular ejection fraction (LVEF) was assessed with
cardiac MRI 24 h post-MI and with ultrasound 28 days later (for a
technical comparison of both techniques see supplemental Fig 1
and 2 in File S1). LVEF in the riociguat-treated mice was much
greater compared to control at this early time-point (Fig 2C). After
28 days, echocardiography still revealed a markedly greater LVEF
in the riociguat treated mice (Fig 4, supplemental Table 2 in File
S1), suggesting a long-lasting beneficial effect of a single dose of
riociguat administered at the time of reperfusion. The preserved
LVEF at 28 days was highly correlated with infarct size 24 h post
MI in the same animals (R2 = 0.85, supplemental Fig 2 in File S1).
MRI also allowed us to measure the ventricular wall’s radial and
circumferential strains one day post-MI. Radial strain is an
indicator of the change in wall thickness during contraction.
Hearts treated with riociguat had greater radial strain, indicating
more wall thickening during systole when compared to the control
group (Fig 5A). Circumferential strain reflecting circumferential
shortening with systole and healthy myocytes should have negative
values. Fig 5B shows a clear improvement in both strains for hearts
treated with riociguat.
Effects of riociguat on hemodynamics
Blood pressure measurements during the open-chest phase of
myocardial infarction via an LV catheter showed a mild drop and
a slightly slower recovery in mean blood pressure after the infusion
of riociguat (Fig 6A). These differences did not reach significance,
however. While this trend was still seen at 24 h post-MI, it was not
seen at any of the later stages between the groups (Fig 6B). Heart
rate was not significantly different in the control animals compared
to riociguat treated mice. (Supplemental Fig 3 in File S1).
Effects of riociguat on cardiac fibrotic tissue remodelling
After sacrifice at 28 days, mRNA gene expression profiles in left
ventricles of the mice were quantified by RT-PCR in order to
characterize tissue remodelling processes. Although not significant,
the average expression of Collagenes (Col1a1, Col3a1, Col4a1,
Col6a1) were slightly less in myocardium of riociguat-treated mice
compared to that in the untreated controls. This may indicate an
attenuated fibrotic tissue remodelling process in the ventricle,
when sGC activity is stimulated at the onset of myocardial
reperfusion. Consistent with reduced expression of extracellular
matrix molecules after riociguat treatment, other pro-fibrotic gene
activities also tended to be expressed at a lesser extent, i.e. MCP-1
(Ccl2), tenascin C, ST2 (Il1rl1), galectin-3 or lipocalin-2 (Fig 7).
Unfortunately none of the values in Fig 7 reached significance.
Discussion
In this study we present clear evidence for a strong and long-
lasting cardioprotective effect of riociguat, a novel sGC stimulator
in an in vivo mouse model of MI and post-MI CHF. Riociguat not
only acutely reduced infarct size and improved LV function but
the effect persisted over the 28 days of the study. Infarct size was
not only evaluated histologically with TTC staining, but also with
novel state-of-the-art imaging techniques. LGE-MRI and FDG-
PET were used 24 h after reperfusion and revealed beneficial
effects of sGC stimulation on infarct size, cardiac function and
morphology. The follow-up over 28 days showed a sustained
preservation of mechanical function from the single riociguat
treatment at reperfusion indicating that the entire benefit was
derived from preventing acute loss of ventricular muscle.
NO activates PKG by causing SGC to increase cGMP in the
cell. Impairments of the NO-sGC-PKG pathway have been
implicated in various cardiac pathologies, including ischaemia/
reperfusion injury and CHF development. [5] Riociguat is a
potent sGC stimulator, which is currently being investigated in
phase III clinical trials for the treatment of pulmonary hyperten-
sion. Riociguat acts directly on sGC and sensitizes sGC to
endogenous NO. [13,25] In animal models of hypotension
riociguat afforded protection against cardiac and renal end organ
damage [15] and it showed reduced left ventricular weight and
cardiac interstitial fibrosis in low and high renin rats. Furthermore,
in a model of chronic cardiac volume and pressure overload in salt
sensitive rats riociguat reduced systemic hypertension and cardiac
fibrosis as well as increased systolic heart function and survival.
[14,15] In the present study, we could observe a non-significant,
non-sustainable trend towards a mild reduction in systolic blood
pressure in the riociguat-treated animals. We cannot rule out any
effect of the blood pressure changes on infarct size or CHF
Figure 6. Effects of riociguat on hemodynamics. (A) Systolic blood pressure data were obtained by using a LV-catheter during infarct size
measurement in the acute model with 30 min ischaemia followed by 2 h reperfusion. There was a slight blood pressure drop after riociguat injection
compared to the vehicle-treated mice in the control group, although changes are not significant. n = 3. (B) Long term systolic blood pressure data
were obtained by using a tail cuff system. One day after injection of riociguat systolic blood pressure still showed a mild trend towards lower values,
which fully disappeared later. n = 7.
doi:10.1371/journal.pone.0083910.g006
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development, although it is known that blood pressure reduction
per se does not afford cardioprotection against ischaemia-reperfu-
sion injury [26,27].
In recent years, imaging techniques such as MRI and PET
became available for the functional and morphological assessment
of mouse hearts and allowed non-invasive follow-up studies of MI
and CHF. Here we used state-of-the-art techniques to assess
myocardial function and morphology with the consecutive
combination of LGE-MRI and FDG-PET. While the cardiac
MRI provides accurate functional data on the basis of detailed
morphology, PET is a highly specific complimentary technique
providing functional data on a molecular level. The combination
of both techniques overcomes the clear shortcomings of each one
alone and represents the current gold standard in in vivo cardiac
imaging. When we used LGE-MRI to assess infarct size after 24 h
of reperfusion there was still a clear benefit in the riociguat-treated
animals with smaller infarct sizes and better-preserved LV
function. All the techniques used were highly congruent.
Furthermore, DENSE MRI imaging allowed us to determine
displacement maps and calculate radial and circumferential strain.
[17,22] Both parameters showed a clear benefit of early riociguat-
treatment post-MI with an increase in radial strain, suggesting
thicker cardiac walls, and a reduced circumferential strain,
indicating preserved myocyte contraction. Global values from
tissue deformation imaging have shown high prognostic value for
remodelling in infarct patients, and it has been suggested that these
might more closely reflect myocardial contractility than traditional
measures of systolic function [28].
These non-invasive imaging techniques allowed us to perform a
follow-up of these animals and determine functional parameters
Figure 7. Relative mRNA expression in myocardium of vehicle or riociguat treated mice at day 28 post MI. Riociguat treatment resulted
in a trend towards reduced levels of pro-fibrotic gene expression in MCP-1 (Ccl2), tenascin C, ST2 (Il1rl1), galectin-3 or lipocalin-2. Due to the high
variation, significance was not reached for any of the genes tested gene. n = 7.
doi:10.1371/journal.pone.0083910.g007
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after 28 days via echocardiography. Human data suggests that
remodelling and CHF development is directly correlated to the
extent of the infarcted area after an acute MI. Here we could show
that the infarct size reduction due to early riociguat treatment was
associated with improved LV function after 4 weeks, suggesting
less detrimental post-MI remodelling. This is supported by our
observation that many pro-fibrotic genes show a strong trend for
lower expression in the treated animals’ hearts.
Taken together, the present results indicate that a single dose of
the sGC stimulator riociguat at the end of a 30 min period of
coronary arterial branch occlusion cause an immediate reduction
of infarct size and preservation of cardiac function in mice.
Furthermore, the beneficial effects on cardiac function and
morphology can still be seen 28 days after the ischemic event,
leading to a reduction of CHF. The consecutive combination of
cardiac LGE-MRI and FDG-PET allowed us to accurately assess
infarct size non-invasively in a myocardial infarction model that is
very close to the clinical scenario. We conclude that sGC
stimulation with riociguat is a promising candidate for preventing
post-MI heart failure in acute coronary syndrome patients
undergoing reperfusion therapy.
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Video S1 Merged LGE-MRI/PET video 24 h after
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(WMV)
Acknowledgments
We thank Ziad Mallat (Department of Medicine, Cambridge University)
for sharing the tail cuff blood pressure system, and Keith Burling (Institute
of Clinical Biochemistry, Cambridge University) for the troponin analysis.
Author Contributions
Conceived and designed the experiments: TK J-PS AC SS. Performed the
experiments: CM GB AV AK CHH. Analyzed the data: TK CM GB.
Contributed reagents/materials/analysis tools: AK J-PS. Wrote the paper:
CM TK.
References
1. Ertl G, Frantz S (2005) Healing after myocardial infarction. Cardiovasc Res 66:
22–32.
2. Maas O, Donat U, Frenzel M, Ru¨tz T, Kroemer HK, et al. (2008) Vardenafil
protects isolated rat hearts at reperfusion dependent on GC and PKG.
Br J Pharmacol 154: 25–31.
3. Salloum FN, Takenoshita Y, Ockaili RA, Daoud VP, Chou E, et al. (2007)
Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction
through opening of mitochondrial KATP channels when administered at
reperfusion following ischemia in rabbits. J Mol Cell Cardiol 42: 453–458.
4. Krieg T, Liu Y, Ru¨tz T, Methner C, Yang X-M, et al. (2009) BAY 58-2667, a
nitric oxide-independent guanylyl cyclase activator, pharmacologically post-
conditions rabbit and rat hearts. Eur Heart J 30: 1607–1613.
5. Burley DS, Baxter GF (2007) B-type natriuretic peptide at early reperfusion
limits infarct size in the rat isolated heart. Basic Res Cardiol 102: 529–541.
6. Methner C, Lukowski R, Grube K, Loga F, Smith RAJ, et al. (2013) Protection
through postconditioning or a mitochondria-targeted S-nitrosothiol is unaffected
by cardiomyocyte-selective ablation of protein kinase G. Basic Res Cardiol 108:
337.
7. Sun J, Aponte AM, Kohr MJ, Tong G, Steenbergen C, Murphy E (2013)
Essential role of nitric oxide in acute ischemic preconditioning: S-Nitros(yl)ation
versus sGC/cGMP/PKG signaling? Free Radic Biol Med 54: 105–112.
8. Sun J, Murphy E (2010) Protein S-nitrosylation and cardioprotection. Circ Res
106: 285–296.
9. Prime TA, Blaikie FH, Evans C, Nadtochiy SM, James AM, et al. (2009) A
mitochondria-targeted S-nitrosothiol modulates respiration, nitrosates thiols, and
protects against ischemia-reperfusion injury. Proc Natl Acad Sci USA 106:
10764–10769.
10. Tse MT (2012) Phase III success for first-in-class pulmonary hypertension drug.
Nat Rev Drug Discov 11: 896.
11. Ghofrani H-A, Galie` N, Grimminger F, Gru¨nig E, Humbert M, et al. (2013)
Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med
369: 330–340.
12. Ghofrani H-A, D’Armini AM, Grimminger F, Hoeper MM, Jansa P, et al.
(2013) Riociguat for the treatment of chronic thromboembolic pulmonary
hypertension. N Engl J Med 369: 319–329.
13. Stasch J-P, Pacher P, Evgenov OV (2011) Soluble guanylate cyclase as an
emerging therapeutic target in cardiopulmonary disease. Circulation 123: 2263–
2273.
14. Geschka S, Kretschmer A, Sharkovska Y, Evgenov OV, Lawrenz B, et al. (2011)
Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and
improves survival in salt-sensitive Dahl rats. PLoS One 6: e21853.
15. Sharkovska Y, Kalk P, Lawrenz B, Godes M, Hoffmann LS, et al. (2010) Nitric
oxide-independent stimulation of soluble guanylate cyclase reduces organ
damage in experimental low-renin and high-renin models. J Hypertens 28:
1666–1675.
16. Schmidt K, Tissier R, Ghaleh B, Drogies T, Felix SB, Krieg T (2010)
Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion.
Eur Heart J 31: 1655–1662.
17. Gilson WD, Yang Z, French BA, Epstein FH (2005) Measurement of myocardial
mechanics in mice before and after infarction using multislice displacement-
encoded MRI with 3D motion encoding. Am J Physiol Heart Circ Physiol 288:
H1491–H1497.
18. Epstein FH, Gilson WD (2004) Displacement-encoded cardiac MRI using cosine
and sine modulation to eliminate (CANSEL) artifact-generating echoes. Magn
Reson Med 52: 774–781.
19. Buonincontri G, Methner C, Krieg T, Carpenter TA, Sawiak SJ (2013) A fast
protocol for infarct quantification in mice. J Magn Reson Imaging 38: 468–473.
20. Hawkes RC, Fryer TD, Siegel S, Ansorge RE, Carpenter TA (2010) Preliminary
evaluation of a combined microPET-MR system. Technol Cancer Res Treat 9:
53–60.
21. Heiberg E, Sjo¨gren J, Ugander M, Carlsson M, Engblom H, Arheden H (2010)
Design and validation of Segment - freely available software for cardiovascular
image analysis. BMC Med Imaging 10: 1.
22. Flynn TJ (1997) Two-dimensional phase unwrapping with minimum weighted
discontinuity. J Opt Soc Am 14: 2692–2701.
23. Sawiak SJ, Wood NI, Williams GB, Morton AJ, Carpenter TA (2009) Voxel-
based morphometry in the R6/2 transgenic mouse reveals differences between
genotypes not seen with manual 2D morphometry. Neurobiol Dis 33: 20–27.
24. Stegger L, Hoffmeier A-N, Scha¨fers KP, Hermann S, Schober O, et al. (2006)
Accurate noninvasive measurement of infarct size in mice with high-resolution
PET. J Nucl Med 47: 1837–1844.
25. Ott IM, Alter ML, von Websky K, Kretschmer A, Tsuprykov O, et al. (2012)
Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in
diabetic eNOS knockout mice on top of angiotensin II receptor blockade. PLoS
One 7: e42623.
26. Maroko PR, Kjekshus JK, Sobel BE, Watanabe T, Covell JW, et al. (1971)
Factors influencing infarct size following experimental coronary artery
occlusions. Circulation 43: 67–82.
27. Maroko PR, Braunwald E (1976) Effects of metabolic and pharmacologic
interventions on myocardial infarct size following coronary occlusion. Circula-
tion53(3 Suppl): 162–168.
28. Hung CL, Verma A, Uno H, Shin SH, Bourgoun M, et al. (2010) Longitudinal
and circumferential strain rate, left ventricular remodeling, and prognosis after
myocardial infarction. J Am Coll Cardiol 56: 1812–1822.
Cardioprotection of Riociguat Post-Infarct
PLOS ONE | www.plosone.org 8 December 2013 | Volume 8 | Issue 12 | e83910
